TR200100840T2 - Benzamid türevleri ve bunların sitokin inhibe edicileri olarak kullanımı - Google Patents

Benzamid türevleri ve bunların sitokin inhibe edicileri olarak kullanımı

Info

Publication number
TR200100840T2
TR200100840T2 TR2001/00840T TR200100840T TR200100840T2 TR 200100840 T2 TR200100840 T2 TR 200100840T2 TR 2001/00840 T TR2001/00840 T TR 2001/00840T TR 200100840 T TR200100840 T TR 200100840T TR 200100840 T2 TR200100840 T2 TR 200100840T2
Authority
TR
Turkey
Prior art keywords
alkyl
alkoxy
amino
heteroaryl
benzamide derivatives
Prior art date
Application number
TR2001/00840T
Other languages
English (en)
Inventor
Sutherland Brown Dearg
Robert Brown George
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9820770.7A external-priority patent/GB9820770D0/en
Priority claimed from GBGB9826938.4A external-priority patent/GB9826938D0/en
Priority claimed from GBGB9905969.3A external-priority patent/GB9905969D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of TR200100840T2 publication Critical patent/TR200100840T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D333/70—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

Bulus, formül I'in amid türevleri, veya bunun farmasötik olarak-kabul edilebilir tuzlari veya in-vivo-yarilabilir esterleri, bunlarin içerildigi farmasötik bilesimler ve hazirlama islemleri, sitokinlerin ortam sagladigi hastaliklarin veya tibbi durumlarin tedavisinde kullanimi ile ilgilidir; burada R3 (1-6c)alkil, halojeno; m, 0-3; p, 0-2; ve q, 0-4 olmaktadir; her bir R1 ve R2 hidroksi, halojeno, trifluorometil, siyano; R4, amino, (1-6c)alkilamino,di-[(1-6c)alkil]amino, di-[(1-6c)alkil] amino(1-6c)alkil, di-[(1-6c)alkil] amino-(2-6c)alkoksi, heteroaril, heteroariloksi, heteroaril-(1-6c) alkoksi, heterosiklil, heterosikliloksi, heterosiklil-(1-6c) alkoksi gibi bazik; heteroaril-(1-6c) alkoksi gibi bir gruptur;
TR2001/00840T 1998-09-25 1999-09-21 Benzamid türevleri ve bunların sitokin inhibe edicileri olarak kullanımı TR200100840T2 (tr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9820770.7A GB9820770D0 (en) 1998-09-25 1998-09-25 Amide derivatives
GBGB9826938.4A GB9826938D0 (en) 1998-12-09 1998-12-09 Amide derivatives
GBGB9905969.3A GB9905969D0 (en) 1999-03-17 1999-03-17 Amide derivatives

Publications (1)

Publication Number Publication Date
TR200100840T2 true TR200100840T2 (tr) 2001-10-22

Family

ID=27269489

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/00840T TR200100840T2 (tr) 1998-09-25 1999-09-21 Benzamid türevleri ve bunların sitokin inhibe edicileri olarak kullanımı

Country Status (24)

Country Link
US (1) US6455520B1 (tr)
EP (1) EP1115707B1 (tr)
JP (1) JP2002525358A (tr)
KR (1) KR100618074B1 (tr)
CN (1) CN1146542C (tr)
AT (1) ATE254105T1 (tr)
AU (1) AU761361B2 (tr)
BR (1) BR9913947A (tr)
CA (1) CA2340454A1 (tr)
DE (1) DE69912823T2 (tr)
DK (1) DK1115707T3 (tr)
ES (1) ES2211172T3 (tr)
HK (1) HK1038556A1 (tr)
HU (1) HUP0104060A3 (tr)
ID (1) ID28267A (tr)
IL (2) IL141979A0 (tr)
NO (1) NO318800B1 (tr)
NZ (1) NZ509836A (tr)
PL (1) PL346854A1 (tr)
PT (1) PT1115707E (tr)
RU (1) RU2219171C2 (tr)
SK (1) SK285520B6 (tr)
TR (1) TR200100840T2 (tr)
WO (1) WO2000018738A1 (tr)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772432B2 (en) * 1991-09-19 2010-08-10 Astrazeneca Ab Amidobenzamide derivatives which are useful as cytokine inhibitors
GB9816837D0 (en) 1998-08-04 1998-09-30 Zeneca Ltd Amide derivatives
US6171705B1 (en) 1997-02-10 2001-01-09 Dofasco, Inc. Structural panel and method of manufacture
DK1017378T3 (da) 1997-09-23 2003-03-17 Astrazeneca Ab Amidderivater til behandling af sygdomme medieret af cytokiner
AU749293B2 (en) 1998-05-15 2002-06-20 Astrazeneca Ab Benzamide derivatives for the treatment of diseases mediated by cytokines
PT1077930E (pt) 1998-05-15 2005-03-31 Astrazeneca Ab Derivados de benzamida para o tratamento de doencas mediadas por citocinas
WO2000007991A1 (en) 1998-08-04 2000-02-17 Astrazeneca Ab Amide derivatives useful as inhibitors of the production of cytokines
ES2221426T3 (es) * 1998-08-20 2004-12-16 Smithkline Beecham Corporation Nuevos compuestos de triazol sustituidos.
DE69912823T2 (de) 1998-09-25 2004-09-23 Astrazeneca Ab Benzamid-derivate und ihre verwendung als cytokine inhibitoren
EP1163237B1 (en) 1999-03-17 2004-05-06 AstraZeneca AB Amide derivatives
WO2000055120A1 (en) * 1999-03-17 2000-09-21 Astrazeneca Ab Amide derivatives
GB9906566D0 (en) 1999-03-23 1999-05-19 Zeneca Ltd Chemical compounds
GB9924092D0 (en) 1999-10-13 1999-12-15 Zeneca Ltd Pyrimidine derivatives
US6759410B1 (en) * 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
US6943161B2 (en) 1999-12-28 2005-09-13 Pharmacopela Drug Discovery, Inc. Pyrimidine and triazine kinase inhibitors
UA76977C2 (en) 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
JP2004531571A (ja) 2001-05-25 2004-10-14 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド サイトカイン生産のインヒビターとしてのカルバメート及びオキサミド化合物
GB0202873D0 (en) 2002-02-07 2002-03-27 Novartis Ag Organic compounds
CA2478232C (en) * 2002-04-11 2011-06-14 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic amide derivatives as cytokine inhibitors
US20060063782A1 (en) * 2002-07-03 2006-03-23 Murray Christopher W 3-Hetero arylmethoxy ! pyridines and their analogues as p38 map kinase inhibitors
EP1534282B1 (en) 2002-07-09 2006-12-27 Boehringer Ingelheim Pharma GmbH & Co.KG Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
ATE329909T1 (de) 2002-11-27 2006-07-15 Boehringer Ingelheim Pharma 1,2,3-triazolamid-derivate als cytokininhibitoren
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US7279576B2 (en) 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments
PL1618092T3 (pl) * 2003-05-01 2011-02-28 Bristol Myers Squibb Co Związki amidopirazolowe z podstawnikami arylowymi jako inhibitory kinazy
EP1643991B1 (en) * 2003-07-11 2014-03-12 Merck Patent GmbH Benzimidazole carboxamides as raf kinase inhibitors
JP4895811B2 (ja) 2003-09-11 2012-03-14 ケミア，インコーポレイテッド サイトカイン阻害剤
GB0324790D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Amide derivatives
US7511042B2 (en) 2003-12-03 2009-03-31 Boehringer Ingelheim Pharmaceuticals, Inc. Triazole compounds
MXPA06014909A (es) 2004-06-18 2007-02-28 Chiron Corp Derivados de n-(1-(1-bencil -4-fenil-1h -imidazol -2-il)-2, 2-dimetilpropil) benzamida y compuestos relacionados como inhibidores de proteina de huso de cinesina (ksp) para el tratamiento del cancer.
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
WO2007024754A1 (en) * 2005-08-22 2007-03-01 Amgen Inc. Bis-aryl urea compounds for the treatment of protein kinase-mediated diseaes
JP5225857B2 (ja) * 2005-11-14 2013-07-03 ジェネンテック，インコーポレイティド ヘッジホッグシグナル伝達のビスアミド阻害剤
CN101611024A (zh) * 2006-12-20 2009-12-23 百时美施贵宝公司 芳基-取代的吡唑-酰胺化合物的晶形
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
EP2183224B1 (en) 2007-08-08 2013-11-06 Merck Serono S.A. 6-amino-pyrimidine-4-carboxamide derivatives and related compounds which bind to the sphingosine 1-phosphate (s1p) receptor for the treatment of multiple sclerosis
BRPI0916576A2 (pt) * 2008-08-04 2017-06-27 Chdi Inc pelo menos uma entidade química, composição farmacêutica, e, método para tratar uma condição ou distúrbio.
WO2012040636A2 (en) * 2010-09-24 2012-03-29 The Broad Institute, Inc. Compounds and methods for treating diseases mediated by protease activated receptors
CN102125038B (zh) * 2010-12-21 2014-01-01 中国船舶重工集团公司第七二五研究所 一种含丹皮酚和烟碱结构的防污剂及其制备方法
MX364378B (es) 2011-08-30 2019-01-21 Chdi Foundation Inc Inhibidores de la quinurenina-3-monooxigenasa, sus composiciones farmaceuticas y metodos para uso.
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
US20150238466A1 (en) * 2012-06-28 2015-08-27 Ramot At Tel-Aviv University Ltd. Lim kinase inhibitors
GB201317609D0 (en) 2013-10-04 2013-11-20 Cancer Rec Tech Ltd Inhibitor compounds
WO2015089479A1 (en) 2013-12-13 2015-06-18 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
EP3079682A4 (en) * 2013-12-13 2017-08-30 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
MX2017000779A (es) 2014-07-17 2017-07-27 Chdi Foundation Inc Metodos y composiciones para el tratamiento de trastornos relacionados con el vih.
CA2965178C (en) 2014-10-22 2023-09-26 Dana-Farber Cancer Institute, Inc. Thiazolyl-containing compounds for treating proliferative diseases
GB201505658D0 (en) * 2015-04-01 2015-05-13 Cancer Rec Tech Ltd Inhibitor compounds
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
GB201617103D0 (en) 2016-10-07 2016-11-23 Cancer Research Technology Limited Compound
TW202122082A (zh) 2019-08-12 2021-06-16 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
MX2022001863A (es) 2019-08-12 2022-05-30 Deciphera Pharmaceuticals Llc Metodos para tratar los tumores del estroma gastrointestinal.
IL293864A (en) 2019-12-30 2022-08-01 Deciphera Pharmaceuticals Llc Preparations of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3- phenylurea
LT4084778T (lt) 2019-12-30 2024-01-25 Deciphera Pharmaceuticals, Llc Amorfinės kinazės inhibitoriaus vaistinės formos ir jų panaudojimo būdai
CA3220039A1 (en) 2021-06-14 2022-12-22 Jr. David St. Jean Urea derivatives which can be used to treat cancer
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1903899A (en) 1933-04-18 Cabboxylic acid abylides oe the benzene sebies and process oe making
DE522788C (de) 1928-11-01 1931-04-15 I G Farbenindustrie Akt Ges Verfahren zur Darstellung von Carbonsaeurearyliden der Benzolreihe
US1909960A (en) 1929-08-06 1933-05-23 Du Pont Intermediate for azo dyes
NL272900A (tr) 1960-12-23
US3755332A (en) 1971-07-01 1973-08-28 Ciba Geigy Corp Substituted 4 indazolaminoquinolines
DE2812252A1 (de) 1978-03-21 1979-10-04 Bayer Ag 1,2,4-triazol-blockierte polyisocyanate als vernetzer fuer lackbindemittel
US4524168A (en) 1981-11-18 1985-06-18 Ciba-Geigy Corporation Process for the mass coloration of polymers
US4749729A (en) 1984-06-21 1988-06-07 American Cyanamid Company Epoxy resin compositions curable above 160 F. and below 250 F.
WO1993004170A1 (en) 1991-08-23 1993-03-04 The United States Of America Represented By The Secretary, Department Of Health And Human Services Raf protein kinase therapeutics
GB9816837D0 (en) 1998-08-04 1998-09-30 Zeneca Ltd Amide derivatives
GB9314884D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Tricyclic derivatives
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
JPH11510511A (ja) 1995-08-10 1999-09-14 メルク エンド カンパニー インコーポレーテッド ２，５−置換アリールピロール、この化合物を含有する組成物及び使用方法
AU6709596A (en) 1995-08-22 1997-03-19 Japan Tobacco Inc. Amide compounds and use of the same
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
JPH09124571A (ja) * 1995-11-01 1997-05-13 Japan Tobacco Inc アミド化合物及びその用途
GB9604926D0 (en) * 1996-03-08 1996-05-08 Sandoz Ltd Organic compounds
JP2001506230A (ja) 1996-08-09 2001-05-15 スミスクライン・ビーチャム・コーポレイション 新規ピペラジン含有化合物
GB9623833D0 (en) 1996-11-16 1997-01-08 Zeneca Ltd Chemical compound
DK1017378T3 (da) 1997-09-23 2003-03-17 Astrazeneca Ab Amidderivater til behandling af sygdomme medieret af cytokiner
AU749293B2 (en) 1998-05-15 2002-06-20 Astrazeneca Ab Benzamide derivatives for the treatment of diseases mediated by cytokines
PT1077930E (pt) 1998-05-15 2005-03-31 Astrazeneca Ab Derivados de benzamida para o tratamento de doencas mediadas por citocinas
WO2000007991A1 (en) 1998-08-04 2000-02-17 Astrazeneca Ab Amide derivatives useful as inhibitors of the production of cytokines
DE69912823T2 (de) 1998-09-25 2004-09-23 Astrazeneca Ab Benzamid-derivate und ihre verwendung als cytokine inhibitoren
IL142257A0 (en) 1998-10-01 2002-03-10 Astrazeneca Ab Amide derivatives, process for their preparation, compositions containing them and use thereof in the manufacture of a medicament for the treatment of cytokine-mediated diseases
EP1163237B1 (en) 1999-03-17 2004-05-06 AstraZeneca AB Amide derivatives
WO2000055120A1 (en) 1999-03-17 2000-09-21 Astrazeneca Ab Amide derivatives
GB9906566D0 (en) 1999-03-23 1999-05-19 Zeneca Ltd Chemical compounds
GB9924092D0 (en) 1999-10-13 1999-12-15 Zeneca Ltd Pyrimidine derivatives

Also Published As

Publication number Publication date
PT1115707E (pt) 2004-04-30
SK285520B6 (sk) 2007-03-01
JP2002525358A (ja) 2002-08-13
NO20011492D0 (no) 2001-03-23
HUP0104060A3 (en) 2002-04-29
IL141979A0 (en) 2002-03-10
DE69912823T2 (de) 2004-09-23
CA2340454A1 (en) 2000-04-06
RU2219171C2 (ru) 2003-12-20
IL141979A (en) 2006-08-20
EP1115707A1 (en) 2001-07-18
DE69912823D1 (de) 2003-12-18
ID28267A (id) 2001-05-10
BR9913947A (pt) 2001-06-12
AU6103499A (en) 2000-04-17
KR100618074B1 (ko) 2006-08-30
HUP0104060A2 (hu) 2002-03-28
ATE254105T1 (de) 2003-11-15
AU761361B2 (en) 2003-06-05
KR20010085828A (ko) 2001-09-07
DK1115707T3 (da) 2004-03-01
CN1319092A (zh) 2001-10-24
HK1038556A1 (en) 2002-03-22
WO2000018738A1 (en) 2000-04-06
US6455520B1 (en) 2002-09-24
CN1146542C (zh) 2004-04-21
NO318800B1 (no) 2005-05-09
ES2211172T3 (es) 2004-07-01
NO20011492L (no) 2001-05-23
NZ509836A (en) 2003-06-30
SK4212001A3 (en) 2001-08-06
EP1115707B1 (en) 2003-11-12
PL346854A1 (en) 2002-03-11

Similar Documents

Publication Publication Date Title
TR200100840T2 (tr) Benzamid türevleri ve bunların sitokin inhibe edicileri olarak kullanımı
TR200100300T2 (tr) Sitokinlerin üretiminde engelleyici olarak kullanışlı amid türevleri
PL345809A1 (en) Amide derivatives which are useful as cytokine inhibitors
NO20021728L (no) Pyrimidin derivater
MY128501A (en) Amide derivatives
DE60022328D1 (de) Amid-derivate
HUP0400710A2 (hu) Tioéter helyettesítővel helyettesített imidazokinolinszármazékok, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
DE60334248D1 (de) Tetrahydro-4h-pyridoä1,2-aüpyrimidine und verwandte verbindungen verwendbar als hiv integrase hemmer
ATE375984T1 (de) Chinazolin derivate
GEP19991869B (en) Amino Acid Derivatives of Substituted Quinoxaline 2,3-Dione Derivatives as Glutamate Receptor Antagonists
ADMIXTURE N-SUBSTITUTED IMIDAZOLES AND THEIR USE IN PHARMACEUTICAL AGENTS
RU2000111253A (ru) Способы и композиции для лечения ревматоидного артрита